A new study suggests that biotech companies are spending far less than believed on research and development for approved drugs, despite rising prices.
Published: September 11, 2017 at 02:00AM
from NYT Health https://ift.tt/2vPB8zT
A new study suggests that biotech companies are spending far less than believed on research and development for approved drugs, despite rising prices.
Published: September 11, 2017 at 02:00AM
from NYT Health https://ift.tt/2vPB8zT
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Google reCAPTCHA helps protect websites from spam and abuse by verifying user interactions through challenges.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)